Efficacy of snail caviar protein powder incorporated into a topical formulation for strengthening the skin structure

Clinical evaluation of the efficacy of snail caviar–derived protein powder as an active raw material in the formulation of a topical product to enhance skin structure integrity

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220313054265N2

Enrollment

Registered

2026-02-18

Start date

2026-03-06

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: skin dehydration. Condition 2: reduced skin elasticity. Condition 3: skin laxity, and decreased collagen content. Condition 4: decreased collagen content. Condition 5: Cutaneous aging. Condition 6: Skin psoriasis. Condition 7: Eczema/Contact dermatitis. Psoriasis Allergic contact dermatitis

Interventions

Intervention 1: Intervention group: the intervention group includes patients who have used product containing protein powder. In the intervention group, each patient is evaluated before and after usin

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: All patients with superficial and deep skin wrinkles All patients with signs of skin laxity and reduced collagen levels/content All patients with degradation of the skin extracellular matrix structure All patients with signs of decreased skin elasticity All patients with eczema, psoriasis, or skin dryness

Exclusion criteria

Exclusion criteria: All patients with autoimmune disorders, except skin psoriasis All patients with skin cancer

Design outcomes

Primary

Measure	Time frame
Skin sensitivity. Timepoint: At the beginning of phase II of the study (before initiation of the intervention) for both groups (intervention and control), and on days 1, 3, and 7 after the start of topical product use. Method of measurement: Clinical evaluation of the skin by a board-certified dermatologist through direct examination and documentation of cutaneous hypersensitivity signs, including erythema, swelling, pruritus, and inflammation at the application site.;The level of effectiveness. Timepoint: The level of effectiveness in reducing or halting the skin disorder will be assessed at the beginning of Phase III of the study (baseline, prior to initiation of the intervention), and subsequently at week 4 (end of the first month), week 8 (second month), and week 12 (third month) after initiation of product use. Method of measurement: Assessment of the level of the product’s efficacy using a researcher-developed questionnaire, along with clinical evaluation of the skin lesion through direct examination and qualitative observation by a board-certified dermatologist.	—

Measure

Time frame

Skin sensitivity. Timepoint: At the beginning of phase II of the study (before initiation of the intervention) for both groups (intervention and control), and on days 1, 3, and 7 after the start of topical product use. Method of measurement: Clinical evaluation of the skin by a board-certified dermatologist through direct examination and documentation of cutaneous hypersensitivity signs, including erythema, swelling, pruritus, and inflammation at the application site.;The level of effectiveness. Timepoint: The level of effectiveness in reducing or halting the skin disorder will be assessed at the beginning of Phase III of the study (baseline, prior to initiation of the intervention), and subsequently at week 4 (end of the first month), week 8 (second month), and week 12 (third month) after initiation of product use. Method of measurement: Assessment of the level of the product’s efficacy using a researcher-developed questionnaire, along with clinical evaluation of the skin lesion through direct examination and qualitative observation by a board-certified dermatologist.

—

Secondary

Measure	Time frame
The speed of effectiveness. Timepoint: The speed of effectiveness in reducing or halting the skin disorder will be assessed at the beginning of Phase III of the study (baseline, prior to initiation of the intervention), and subsequently at week 4 (end of the first month), week 8 (second month) and week 12 (third month) after initiation of product use. Method of measurement: Assessment of the speed of the product’s efficacy using a researcher-developed questionnaire, along with clinical evaluation of the skin lesion through direct examination and qualitative observation by a board-certified dermatologist.	—

Measure

Time frame

The speed of effectiveness. Timepoint: The speed of effectiveness in reducing or halting the skin disorder will be assessed at the beginning of Phase III of the study (baseline, prior to initiation of the intervention), and subsequently at week 4 (end of the first month), week 8 (second month) and week 12 (third month) after initiation of product use. Method of measurement: Assessment of the speed of the product’s efficacy using a researcher-developed questionnaire, along with clinical evaluation of the skin lesion through direct examination and qualitative observation by a board-certified dermatologist.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzadeh Izadyari Aghmiuni

Nano Oxin Daroo Company

azadeh.izadyari@gmail.com+98 21 5574 5527

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026